WIG 2001
Alternative Names: WIG-2001Latest Information Update: 14 Apr 2022
At a glance
- Originator Whanin Pharmaceutical
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Arterial occlusive disorders
Most Recent Events
- 14 Apr 2022 Phase-I clinical trials in Arterial occlusive disorders in South Korea (unspecified route) (Whanin Pharmaceutical pipeline, April 2022)
- 19 Jul 2021 WIG 2001 is available for licensing as of 21 Jul 2021. https://www.whanin.com/_commonBase/content.php?co_id=outlicense_kor# (Whanin Pharmaceutical website, July 2021)
- 19 Jul 2021 Early research in Arterial occlusive disorders in South Korea (unspecified route) before July 2021 (Whanin Pharmaceutical pipeline, July 2021)